Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Leopoldstr. 5, 80802, Munich, Germany.
German Center for Infection Research (DZIF), Partner Site Munich, Leopoldstr. 5, 80802, Munich, Germany.
Malar J. 2018 Jun 26;17(1):245. doi: 10.1186/s12936-018-2389-z.
A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanzania.
Between 2005 and 2011, a large general population cohort in the Mbeya Region in the south-west of Tanzania has been surveyed within the EMINI-study (Evaluation and Monitoring of the Impact of New Interventions). Participants were examined once per year, including rapid diagnostic testing for malaria. ACT was introduced in the region according to national guidelines in the time period 2006/2007, replacing sulfadoxine/pyrimethamine as first-line therapy. In four study sites, 6773 individuals who participated in the first two of three consecutive survey visits in the period from 2006 to 2009 were included in this analysis. The prevalence of Plasmodium infection prior to and after the introduction of ACT was compared by logistic regression, with consideration of climatic variability, age, sex, socio-economic status and bed net use as potential confounders.
A significant reduction over time in the prevalence of Plasmodium falciparum infection from 2.5 to 0.3% was shown across the four study sites. The decline was not explained by other factors included in the analysis, therefore, the decline over time most likely reflects the impact of introduction of ACT in the study area.
The longitudinal study showed a significant and relevant decline in the prevalence of P. falciparum infection after introduction of ACT, which could not be explained by potential confounders. The data suggests that artemisinin-based combinations are not only an effective instrument for reduction of immediate morbidity and mortality, but also for reduction of transmission rates.
在高疟疾流行国家引入青蒿素为基础的联合疗法(ACT)后,疟疾发病率和死亡率显著下降。到目前为止,关于 ACT 的影响以及疟疾的流行情况,在坦桑尼亚西南部的数据还很有限。
在 2005 年至 2011 年期间,坦桑尼亚西南部姆贝亚地区的一项大型一般人群队列研究(新干预措施的评估和监测)在范围内进行。参与者每年接受一次检查,包括疟疾快速诊断检测。ACT 于 2006/2007 年期间根据国家指南在该地区推出,取代了磺胺多辛/乙胺嘧啶作为一线治疗。在四个研究地点,共有 6773 名在 2006 年至 2009 年期间连续三次调查访问的前两次参加了这项分析的个体被纳入了这项分析。通过逻辑回归比较了引入 ACT 前后疟原虫感染的流行率,同时考虑了气候变异性、年龄、性别、社会经济地位和蚊帐使用等潜在混杂因素。
四个研究地点均显示,疟原虫感染的流行率从 2.5%显著下降到 0.3%。这种下降不能用分析中纳入的其他因素来解释,因此,时间上的下降很可能反映了 ACT 在研究区域的引入的影响。
这项纵向研究显示,在引入 ACT 后,疟原虫感染的流行率显著下降,这不能用潜在的混杂因素来解释。数据表明,青蒿素类复方不仅是减少即时发病率和死亡率的有效手段,也是减少传播率的有效手段。